Postoperative body-weight loss and survival after curative resection for gastric cancer

2002 ◽  
Vol 89 (4) ◽  
pp. 467-470 ◽  
Author(s):  
W. Yu ◽  
B. Y. Seo ◽  
H. Y. Chung
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Curative Resection ◽  
Body Weight Loss

1122 A phase III trial to confirm preventing effects of perioperative enteral EPA-enriched immunonutrition on body weight loss after total gastrectomy for gastric cancer

2015 ◽  
Vol 51 ◽  
pp. S171
Author(s):  
N. Hiki ◽  
T. Yoshikawa ◽  
K. Sakamaki ◽  
S. Ito ◽  
K. Fujitani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Total Gastrectomy ◽  
Body Weight Loss ◽  
Phase Iii ◽  
Phase Iii Trial

scholarly journals Long‐term effects of an oral elemental nutritional supplement on post‐gastrectomy body weight loss in gastric cancer patients (KSES002)

2019 ◽  
Vol 3 (6) ◽  
pp. 648-656 ◽  
Author(s):  
Yutaka Kimura ◽  
Kazuhiro Nishikawa ◽  
Kentaro Kishi ◽  
Kentaro Inoue ◽  
Jin Matsuyama ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Cancer Patients ◽  
Body Weight Loss ◽  
Nutritional Supplement ◽  
Long Term Effects ◽  
Gastric Cancer Patients

Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment

2021 ◽  
pp. 1-14
Author(s):  
Takuro Mizukami ◽  
Koki Hamaji ◽  
Risa Onuki ◽  
Ayako Yokomizo ◽  
Yoshie Nagashima ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Advanced Gastric Cancer ◽  
Body Weight Loss ◽  
Line Treatment ◽  
Second Line

scholarly journals Clinical outcomes of proximal gastrectomy for gastric cancer: A comparison between the double-flap technique and jejunal interposition

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0247636
Author(s):  
Tsutomu Kumamoto ◽  
Mitsuru Sasako ◽  
Yoshinori Ishida ◽  
Yasunori Kurahashi ◽  
Hisashi Shinohara
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Nutritional Status ◽  
Clinical Outcomes ◽  
Surgical Outcomes ◽  
Proximal Gastrectomy ◽  
Body Weight Loss ◽  
Jejunal Interposition ◽  
Flap Technique

Background The optimal reconstruction method after proximal gastrectomy (PG) has been debatable. Recent reports have shown that the double-flap technique (DFT) provides good outcomes in terms of postoperative nutritional status and quality of life. However, no study has compared the clinical outcomes of the DFT with other reconstruction methods. Here, we evaluated and compared the clinical outcomes between the DFT and jejunal interposition (JI) after PG for gastric cancer. Materials and methods The medical records of 34 consecutive patients who had undergone PG for upper third gastric cancer between January 2011 and October 2016 were reviewed retrospectively. The main factors investigated were surgical outcomes, postoperative nutritional status, symptoms, and endoscopic findings 1 year after surgery. Results Thirty-four patients were enrolled (DFT, 14; JI, 20). The operation time was similar between the two techniques (228 and 246 minutes for DFT and JI, respectively, P = 0.377), as were the rates of anastomotic complications (7% and 0% for DFT and JI, respectively, P = 0.412). Body weight loss was significantly lower in the DFT group than in the JI group (-8.1% vs -16.1%, P = 0.001). Total protein and albumin levels were higher in the DFT group than in the JI group (0% vs -2.9%, P = 0.053, and -0.3% vs -6.1%, P = 0.077, respectively). One patient in the DFT group and no patients in the JI group experienced reflux esophagitis (≥ grade B) (P = 0.393). Anastomotic strictures were not observed as postoperative complications in either group. Conclusions Surgical outcomes revealed that the DFT was safe and feasible, similar to JI. In terms of controlling postoperative body weight loss, the DFT is a better reconstruction technique than JI after PG.

Randomized controlled trial comparing Billroth-I and Roux-en-Y reconstruction in distal gastrectomy for gastric cancer.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 65-65 ◽  
Author(s):  
J. Fujita ◽  
H. Imamura ◽  
S. Takiguchi ◽  
K. Fujitani ◽  
I. Miyashiro ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Postoperative Morbidity ◽  
Distal Gastrectomy ◽  
Controlled Trial ◽  
Body Weight Loss ◽  
The Body ◽  
Billroth I ◽  
Randomized Controlled

65 Background: In distal subtotal gastrectomy for gastric cancer, Billroth-I (B-I) reconstruction has been performed predominantly in Japan, while increasing number of surgeons chose Roux-en-Y (R-Y) reconstruction recently. To evaluate the safety and superiority of R-Y we conducted a multi-institutional prospective randomized controlled trial. Methods: Gastric cancer patients who underwent distal gastrectomy were randomized to B-I or R-Y intraoperatively. The primary endpoint was the ratio of body weight loss 1 year after surgery, the secondary endpoints were the incidence of delayed gastric emptying (DGE) and postoperative morbidity. Results: Between Aug 2005 and Dec 2008, a total of 332 patients were enrolled and 163 patients were assigned to B-I and 169 patients to R- Y. The patient's characteristics were well balanced between the two groups. The operation time was significantly longer in R-Y than B-I (median 180 min in B-I vs 214 min in R-Y, p < 0.0001). The postoperative morbidity was 14 patients (8.6%) in B-I and 23 (13.6%) in R-Y (p = 0.14), the incidence of DGE was 7 (4.3%) in B-I vs 16 (9.5%) in R-Y (p = 0.06), and the hospital stay after surgery was 14.1days in B-I vs 16.4 days in R-Y (p = 0.02). There was no hospital death in the two groups. The body weight loss at 1 year after surgery compared to preoperation was -5.4kg (-9.1%) in B-I vs -6.2kg (-9.8%) in R-Y (p = 0.11). Conclusions: The advantage of R- Y reconstruction compared to B-I was not proved in terms of postoperative morbidity either the body weight loss 1 year after surgery. No significant financial relationships to disclose.

Risk factors that affect continuation of S-1 chemotherapy as an adjuvant setting after radical gastrectomy for gastric cancer.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 151-151
Author(s):  
Daisuke Kobayashi ◽  
Chie Tanaka ◽  
Naoki Iwata ◽  
Mitsuro Kanda ◽  
Suguru Yamada ◽  
...  
Keyword(s):  
Risk Factors ◽  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Adverse Effects ◽  
Body Weight Loss ◽  
Standard Of Care ◽  
Current Standard ◽  
Curative Gastrectomy ◽  
Group 13

151 Background: Based on the evidence from ACTS-GC trial, postoperative S-1 administration for 12 months is the current standard of care in Japan for patients with pathological Stage II/III gastric cancer treated with D2 gastrectomy. However, the proportion of patients who actually tolerated 12 months of treatment in the ACTS-GC trial was 65.8%. In the present study, we explored the risk factors that could affect the compliance of S-1 adjuvant therapy. Methods: This retrospective study selected 68 consecutive patients who underwent curative gastrectomy for gastric cancer and received S-1 chemotherapy at our institution between 2003 and 2012. Associations between S-1 compliance, adverse effects and clinical characteristics were analyzed. Results: 51 patients were male, and 17 were female. Patient age ranged between 20 and 80 years (median: 64.0). 47 patients (69%) completed the prescribed S-1 treatment for 1 year. In addition, 5 patients discontinued treatment due to recurrence within 1 year, and 3 patients due to reasons irrelevant to the S-1 toxicity. These 55 patients were designated as non-AE group. The remaining 13 patients (19%) were obliged to discontinue S-1 due to adverse effects within 1 year (AE group). The percentage of female was higher in the AE group (46% versus 20% in the non-AE group). The median age of patients was significantly higher in the AE group (72 versus 63 in the non-AE group, p=0.004). Although there was no difference in the serum creatinine level at the beginning of the treatment, creatinine clearance (CCr) of AE group was significantly lower at 65 mL/min (83 mL/min for the non-AE group, p=0.04). Median body weight loss during the first 3 postoperative months in the AE group (13% of the original weight) was significantly higher (10% in the non-AE group, p=0.04), although the median body weight before treatment didn’t differ between the two groups. Dose reduction was more diligently conducted among the population with CCr< 60 in the non-AE group (4/7) than in the AE group (1/5). Conclusions: Female, old age, low CCr and greater body weight loss affect compliance of the S-1 adjuvant chemotherapy. Meticulous dose modification is required for those with risk for discontinuation.

scholarly journals A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy

2019 ◽  
Vol 30 ◽  
pp. iv27
Author(s):  
A. Parisi ◽  
A. Cortellini ◽  
M. Roberto ◽  
O. Venditti ◽  
D. Santini ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Body Mass Index ◽  
Weight Loss ◽  
Body Weight ◽  
Real Life ◽  
Body Weight Loss ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Gastric Cancer Patients

Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial

2016 ◽  
Vol 23 (9) ◽  
pp. 2928-2935 ◽  
Author(s):  
Hiroshi Imamura ◽  
Kazuhiro Nishikawa ◽  
Kentaro Kishi ◽  
Kentaro Inoue ◽  
Jin Matsuyama ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Weight Loss ◽  
Body Weight ◽  
Body Weight Loss ◽  
Nutritional Supplement ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Gastric Cancer Patients

MON-PP073: Impact of Body Weight Loss after Gastrectomy on the Postoperative S-1 Chemotherapy for Gastric Cancer

2015 ◽  
Vol 34 ◽  
pp. S154-S155
Author(s):  
D. Kobayashi ◽  
C. Tanaka ◽  
M. Kanda ◽  
N. Iwata ◽  
S. Yamada ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Body Weight Loss

scholarly journals Analysis of factors contributing to postoperative body weight change in patients with gastric cancer: based on generalized estimation equation

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9390
Author(s):  
Qiuju Tian ◽  
Liyuan Qin ◽  
Weiyi Zhu ◽  
Shaojie Xiong ◽  
Beiwen Wu
Keyword(s):  
Gastric Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Cancer Patients ◽  
Total Gastrectomy ◽  
Weight Change ◽  
Body Weight Loss ◽  
Body Weight Change ◽  
Generalized Estimation Equation ◽  
Gastric Cancer Patients

Aims The study aimed to explore factors contributing to body weight change over time in gastric cancer patients after gastrectomy, in order to find risk factors to implement nutritional intervention beforehand. Methods A cohort of gastric cancer patients who were treated with gastrectomy from January to March 2019 at a university affiliated hospital in Shanghai were consecutively identified in this study. Demographics, disease related information, nutrition knowledge, attitude, and practice score were collected before gastrectomy. In addition, body weight before surgery (T0), body weight at one month (T1), two months (T2), and three months (T3) after gastrectomy were recorded. Generalized estimation equation was used to describe body weight change and analyze factors contributing to body weight change after surgery. Results There were 49 patients recruited in the study. Patient body weight decreased by 9.2% at T1 (Wald χ = 271.173, P <0.001), 11.0% at T2 (Wald χ2 = 277.267, P <0.001), and 11.4% at T3 compared to baseline at T0 (Wald χ = 284.076, P <0.001). The results of GEE for multivariable analysis showed that surgery type (Wald χ = 6.027, P = 0.014) and preoperative BMI (Wald χ = 12.662, P = 0.005) were contributing factors of body weight change. Compared with distal gastrectomy patients, total gastrectomy patients experienced greater body weight loss (β = 2.8%, P = 0.014). Compared with patients with BMI&λτ; 18.5 kg/m2, patients with BMI ≥ 25 kg/m2experienced greater body weight loss (β = 4.5% P = 0.026). Conclusion Gastric cancer patients experienced significant weight loss during 3 months after gastrectomy. Total gastrectomy and BMI ≥ 25 kg/m2were risk factors to postoperative body weight loss for GC patients. The results suggested hinted that clinician should pay attention to postoperative nutrition status of patient undergoing total gastrectomy and obesity patients.

Sign in / Sign up

Export Citation Format

Share Document